Health & Biotech
Here’s why Morningstar reckons the ASX healthcare sector is on road to recovery
Health & Biotech
Incannex at forefront of psychedelic research and development with key trial data review kicking off
Health & Biotech
There’s some very good resins why our Little Green Pharma is already leading the 2023 German invasion
Health & Biotech
ScoPo’s Powerplays: Volpara leads a minor ASX small cap health sector renaissance
Health & Biotech
ASX Health Stocks: Mayne Pharma launches women contraceptives in US, Oventus’ administrators take over
Health & Biotech
Dimerix gets US FDA nod to recruit adolescents to Phase III FSGS trial
Health & Biotech
MedLab reports good interim readouts on NanaBis, gives confidence for Phase III trial
Health & Biotech
Weed Week: Snoop Dogg releases Death Row Cannabis and Aussie player hits the German market
Health & Biotech
NGS launches clinical trial on supplements for young athletes, targets the $80 billion sports nutrition market
Health & Biotech
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta
Health & Biotech
Off to a good start: Wellnex Life records 54% revenue increase in H1 FY23
Health & Biotech
ASX Health Stocks: LBT Innovations picked by AstraZeneca as partner, share price surges 22pc
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.